Jaguar Health Inc
NASDAQ:JAGX
Jaguar Health Inc
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
Revenue Growth: Quarterly revenue reached approximately $3.1 million, up about 4% from Q2 2025 and flat year-on-year.
Clinical Progress: Crofelemer showed a significant reduction in parenteral support for rare disease patients, with up to a 37% reduction in MVID and 12% in short bowel syndrome.
Pipeline Milestones: Multiple late-stage clinical and regulatory catalysts anticipated, including potential expedited review for two human indications and an animal health partnership.
Loss Reduction: Net loss attributable to common shareholders decreased by $352,000 year-over-year.
Business Development: Ongoing negotiations for non-dilutive partnerships in both human and animal health segments.
Product Expansion: Plans for Mytesi label extension into cancer therapy-related diarrhea and expanded indications for Canalevia in animal health.
